Citius Oncology (CTOR) to Release Earnings on Wednesday

Citius Oncology (NASDAQ:CTOR) will likely be issuing its resultson Wednesday, May 20th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $6.9970 million for the quarter.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings data on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). The business had revenue of $3.94 million during the quarter, compared to analyst estimates of $4.37 million.

Citius Oncology Trading Down 0.1%

Shares of CTOR stock opened at $0.90 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.32 and a current ratio of 0.83. The stock has a market capitalization of $79.74 million, a P/E ratio of -2.91 and a beta of 3.56. The company has a 50 day moving average price of $0.81 and a 200 day moving average price of $1.08. Citius Oncology has a fifty-two week low of $0.49 and a fifty-two week high of $6.19.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CTOR. Geode Capital Management LLC grew its holdings in shares of Citius Oncology by 179.0% in the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after purchasing an additional 36,758 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Citius Oncology in the second quarter valued at approximately $465,000. Bank of America Corp DE grew its holdings in shares of Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after purchasing an additional 8,411 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Citius Oncology in the third quarter valued at approximately $36,000. Finally, Armistice Capital LLC acquired a new position in shares of Citius Oncology in the third quarter valued at approximately $15,582,000. Institutional investors and hedge funds own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.